Alkermes Balance Sheet Health

Financial Health criteria checks 6/6

Alkermes has a total shareholder equity of $1.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.1B and $570.4M respectively. Alkermes's EBIT is $391.1M making its interest coverage ratio -14.7. It has cash and short-term investments of $884.0M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ratio-14.7x
CashUS$884.02m
EquityUS$1.51b
Total liabilitiesUS$570.39m
Total assetsUS$2.08b

Recent financial health updates

Recent updates

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

May 01

Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors

Apr 21
Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Feb 25

Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price

Jan 16
Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price

We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt

Dec 17
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 24

Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

Oct 14
Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Sep 17
Is Alkermes (NASDAQ:ALKS) A Risky Investment?
author-image

Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges

Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.

Alkermes: Fairly Valued After Post-Earnings Bump

Jul 28

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Jul 26
Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

Jul 04
Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 09

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Jan 26

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Oct 14

Alkermes holder Sarissa Capital says it may look to increase its stake

Oct 07

Alkermes: Nothing Stands Out As Interesting

Sep 26

Alkermes initiated at neutral at Piper Sandler as company in transition

Aug 16

Alkermes Q2 2022 Earnings Preview

Jul 26

Financial Position Analysis

Short Term Liabilities: ALKS's short term assets ($1.5B) exceed its short term liabilities ($443.7M).

Long Term Liabilities: ALKS's short term assets ($1.5B) exceed its long term liabilities ($126.7M).


Debt to Equity History and Analysis

Debt Level: ALKS is debt free.

Reducing Debt: ALKS has no debt compared to 5 years ago when its debt to equity ratio was 26%.

Debt Coverage: ALKS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ALKS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 21:33
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alkermes plc is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Robert HazlettBMO Capital Markets U.S. (Historical)
Jason Matthew GerberryBofA Global Research